科妍生物科技股份有限公司 Approved
最後更新時間 2025/07/13 , 02:43 AM
最後更新時間 2025/07/13 , 02:43 AM
負責人
Han,Kai-Cheng
統一編號
13159100
成立日期
2001/11/12
資本額
NT$1,000,000,000
實收資本額
NT$721,916,880
股票代號
1786
電話
07-8232258
地址
No. 1, S. 1st Rd., Qianzhen Dist., Kaohsiung City, 806, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Han,Kai-Cheng Chairman 2.62%
Yang,Ming-Gong Director 4.07%
Yang Li,Shu-Lan Director 3.76%
Han,Tai-Wei Director 0.35%
Pan,Zong-Wei Director 0.00%
Guo,Ru-Ling Director 0.61%
Chen,Zhao-Long Independent Director 0.00%
Chen,Rong-Chao Independent Director 0.00%
Chen,Shui-Cong Independent Director 0.00%
營業項目
  • Manufacture of Other Medical Instruments and Supplies(332900)
  • Manufacture of Cosmetics(193299)
  • 公司歷程
  • Change Capital to 1,000,000,000
    2022/07/21
  • Change Capital to 800,000,000
    2014/09/17
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2025 2024 2023
    Operating income 204,335 883,310 712,988
    Operating cost 62,165 227,626 200,494
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 142,170 655,684 512,494
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 142,170 655,684 512,494
    Operating expenses 81,567 407,574 312,856
    Other gain (loss), net - - -
    Operating profit (loss) 60,603 248,110 199,638
    Non-operating income and expenses 13,097 43,488 10,359
    Net profit (loss) before tax 73,700 291,598 209,997
    Income tax expense (benefits) 16,839 49,344 32,097
    Net profit (loss) of ongoing business for the current period 56,861 242,254 177,900
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period 56,861 242,254 177,900
    Other comprehensive profit (loss), net 34 3,830 455
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period 56,895 246,084 178,355
    Net profit (loss) attributable to owners of parent company 56,861 242,254 177,900
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company 56,895 246,084 178,355
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 0 3 2
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities 115,223 269,873 272,012
    Net cash inflows (outflows) from investing activities 78,345 97,516 -213,365
    Net cash inflow (outflow) from financing activities -466 -172,518 -134,530
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 34 50 -33
    Increase (decrease) in cash and cash equivalents in the current period 193,136 194,921 -75,916
    Beginning balance of cash and cash equivalents 706,022 511,101 587,017
    Ending balance of cash and cash equivalents 899,158 706,022 511,101
    項目 2025 2024 2023
    Current asset 1,234,724 1,166,418 1,003,908
    Non-current asset 1,208,996 1,188,058 1,156,262
    Total asset 2,443,720 2,354,476 2,160,170
    Current liability 590,106 337,070 144,992
    Non-current liability 117,684 120,355 388,673
    Total liability 707,790 457,425 533,665
    share capital 721,917 718,547 677,311
    Equity - secruity token - - -
    capital reserve 844,176 844,081 700,339
    retained earning 170,627 335,247 249,731
    Other equity -790 -824 -876
    Treasury stock - - -
    Total equity attributable to owners of parent company 1,735,930 1,897,051 1,626,505
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 1,735,930 1,897,051 1,626,505
    Share capital awaiting retirement (unit: share) - - -
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 24 26 24
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • Protavity
  • 玻達美得
  • 貝利癒
  • Bellyhere
  • 有得力護
  • Utarive
  • 麗復達
  • Neodoma
  • 玻保癒
  • Proregion
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Return security deposit
    2006
  • Payment order
    2007
  • Trademark Evaluation
    2018
  • Trademark opposition
    2018
  • Trademark registration
    2018
  • Infringement damage compensation
    2009, 2010
  • Request for infringement compensation
    2010
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。